American Portfolios Advisors Alaunos Therapeutics, Inc. Transaction History

American Portfolios Advisors

  • $2.36 Trillion
  • Q3 2022

A detailed history of American Portfolios Advisors transactions in Alaunos Therapeutics, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 2,100 shares of TCRT stock, worth $5,019. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,100
Holding current value
$5,019
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023
BUY
$1.04 - $322.5 $2,184 - $677,250
2,100 New
2,100 $3.61 Million
Q2 2021

Mar 22, 2023
SELL
$2.63 - $3.67 $789 - $1,101
-300 Reduced 14.29%
1,800 $4.75 Million
Q1 2021

Mar 22, 2023
SELL
$2.82 - $5.6 $846 - $1,680
-300 Reduced 14.29%
1,800 $6.48 Million
Q4 2020

Mar 22, 2023
SELL
$2.09 - $3.09 $1,672 - $2,472
-800 Reduced 38.1%
1,300 $3.28 Million
Q3 2020

Mar 22, 2023
SELL
$2.39 - $3.43 $1,912 - $2,744
-800 Reduced 38.1%
1,300 $3.28 Million
Q1 2020

Mar 24, 2023
SELL
$1.9 - $4.98 $1,520 - $3,984
-800 Reduced 38.1%
1,300 $3.19 Million
Q4 2019

Mar 24, 2023
SELL
$3.95 - $5.35 $3,160 - $4,280
-800 Reduced 38.1%
1,300 $6.14 Million
Q3 2019

Mar 24, 2023
SELL
$4.13 - $6.94 $16 - $27
-4 Reduced 0.31%
1,300 $5.56 Million
Q2 2019

Mar 24, 2023
SELL
$3.98 - $6.2 $3,168 - $4,935
-796 Reduced 37.9%
1,304 $7.6 Million
Q4 2018

Mar 24, 2023
BUY
$1.61 - $3.62 $2,093 - $4,706
1,300 Added 32500.0%
1,304 $2.44 Million
Q3 2018

Mar 24, 2023
SELL
$2.26 - $3.27 $4,736 - $6,853
-2,096 Reduced 99.81%
4 $13,000
Q1 2018

Mar 24, 2023
SELL
$3.46 - $5.14 $7,252 - $10,773
-2,096 Reduced 99.81%
4 $16,000
Q4 2017

Mar 24, 2023
SELL
$4.0 - $6.54 $8,384 - $13,707
-2,096
4 $17,000

Others Institutions Holding TCRT

# of Institutions
5
Shares Held
92.6K
Call Options Held
0
Put Options Held
0
View Full List

About Alaunos Therapeutics, Inc.

TCRT Quotes by TradingView
  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $517M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email